View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 20, 2019

US Senate permanently repeals medical device excise tax

The US Senate has passed bipartisan legislation to permanently repeal the 2.3% medical device excise tax.

The US Senate has passed bipartisan legislation to permanently repeal the 2.3% medical device excise tax.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Originally enacted as a part of the Affordable Care Act (ACA) in 2013, the medical device tax imposes a 2.3% tax on the domestic sales of medical devices, to be paid by the device manufacturer or importer.

Following a two year moratorium, tax went into effect on 1 January 2016 and was then renewed two weeks into 2018.

In July 2018, the US House of Representatives passed a bill to repeal the tax but the Senate failed to act.

The tax was suspended multiple times in the past. The second moratorium is due to expire at the end of this month.

The spending bill will now go to US President Donald John Trump.

The tax has a significant impact on small and mid-sized companies, based on sales and not profits.

The tax affects nearly 300,000 jobs in the MedTech industry of the US, according to the US Department of Commerce.

If implemented again, the tax is estimated to lead to a loss of 21,390 full-time equivalent jobs and a decrease of $1.7bn in the gross domestic product (GDP).

Medical device trade group Advanced Medical Technology Association (AdvaMed) welcomed repealing of the tax.

AdvaMed president and CEO Scott Whitaker said: “The House vote to repeal the device tax is a huge win for American patients.

“Without this burdensome tax, the US MedTech industry, the world leader in medical innovation, can focus now on developing the next generation of treatments and cures for patients in need, and creating good-paying, high-tech jobs in communities across the country.”

In March, US Senators Pat Toomey and Amy Klobuchar introduced bipartisan legislation to repeal medical device tax across the country.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network